Abstract:Myotonic dystrophy type 1 (DM1) is multisystem disease arising from mutant CTG expansion in the non-translating region of the dystrophia myotonica protein kinase gene. While DM1 is the most common adult muscular dystrophy, with a worldwide prevalence of one in eight thousand, age of onset varies from before birth to adulthood. There is a broad spectrum of clinical severity, ranging from mild to severe, which correlates with number of DNA repeats. Importantly, the early clinical manifestations and management in congenital and childhood DM1 differ from classic adult DM1. In neonates and children, DM1 predominantly affects muscle strength, cognition, respiratory, central nervous and gastrointestinal systems. Sleep disorders are often under recognised yet a significant morbidity. No effective disease modifying treatment is currently available and neonates and children with DM1 may experience severe physical and intellectual disability, which may be life limiting in the most severe forms. Management is currently supportive, incorporating regular surveillance and treatment of manifestations. Novel therapies, which target the gene and the pathogenic mechanism of abnormal splicing are emerging. Genetic counselling is critical in this autosomal dominant genetic disease with variable penetrance and potential maternal anticipation, as is assisting with family planning and undertaking cascade testing to instigate health surveillance in affected family members. This review incorporates discussion of the clinical manifestations and management of congenital and childhood DM1, with a particular focus on hypersomnolence and sleep disorders. In addition, the molecular genetics, mechanisms of disease pathogenesis and development of novel treatment strategies in DM1 will be summarised.

Molecular genetics of congenital myotonic dystrophy

Clinical analysis and gene mutation screening of CLCN1 in two myotonia congenita families

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions

Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing

CCG interruptions are unstable and hypermethylated in DM1 patients

Myotonic dystrophies: an update on clinical features, molecular mechanisms, management, and gene therapy

Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1.

[Clinical and Genetic Analysis of Three Pedigrees Affected with Myotonic Dystrophy].

Congenital myopathies: pathophysiological mechanisms and promising therapies

CTG repeat length underlying cardiac events and sudden death in myotonic dystrophy type 1

Myotonic Dystrophy: Evidence for a Possible Dominant-Negative RNA Mutation

Studies of the Haplotypes of CTG Triplet Repeat and Alu±1kb in DMPK Gene of Myotonic Dystrophy

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Identification of ZNF850 as a novel CTG repeat expansion-related gene in myotonic dystrophy type 1 patient-derived iPSCs

Myotonia Congenita and Myotonic Dystrophy in the Same Family: Coexistence of a CLCN1 Mutation and Expansion in the CNBP (ZNF9) Gene

Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1

Research progress of CTG repeats in structural biology

Cellular Senescence and Aging in Myotonic Dystrophy